For the Inventor, By the Inventor

Enter assignee name

Pasadena, CA, United States of America

Lixte Biotechnology, Inc.

USPTO Granted Patents = 27

EPO Patents = 13

Forward Citations = 268

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

John S Kovach (26 out of 30 patents)

Francis Johnson (10 out of 30 patents)

Robert A Volkmann (5 out of 73 patents)

4. Anthony Marfat (5 out of 62 patents)

5. Mickey L Wells (3 out of 3 patents)

6. Manuel Mameli (2 out of 2 patents)

7. Salvatore Lecca (2 out of 2 patents)

8. Alan F List (1 out of 22 patents)

9. Zhengping Zhuang (1 out of 8 patents)

10. David A Sallman (1 out of 2 patents)

11. Jason J Piotrowski (1 out of 1 patent)

12. Dumitru Ionescu (1 out of 16 patents)

13. Sze Chun Winson Ho (1 out of 1 patent)

14. Herui Wang (1 out of 1 patent)

15. Rongze Lu (1 out of 1 patent)

27 patents: Sort by Forward Citations

1. 12343342 - Methods for treating soft tissue sarcoma (2025-07-01),

2. 12168008 - Oxabicycloheptanes for modulation of immune response (2024-12-17),

3. 11931354 - Formulations of oxabicycloheptanes and oxabicycloheptenes (2024-03-19),

4. 11866444 - Oxabicycloheptane prodrugs (2024-01-09),

5. 11236102 - Oxabicycloheptane prodrugs (2022-02-01),

6. 10668062 - Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes (2020-06-02),

7. 10618908 - Oxabicycloheptane prodrugs (2020-04-14),

8. 10532050 - Formulations of oxabicycloheptanes and oxabicycloheptenes (2020-01-14),

9. 10434100 - Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes (2019-10-08),

10. 10413541 - Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders (2019-09-17),

11. 10399993 - Oxabicycloheptanes and oxabicycloheptenes, their preparation and use (2019-09-03),

12. 10364252 - Oxabicycloheptane prodrugs (2019-07-30),

13. 10149847 - Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes (2018-12-11),

14. 10023587 - Oxabicycloheptanes and oxabicycloheptenes, their preparation and use (2018-07-17),

15. 9994584 - Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid (2018-06-12),

Lixte Biotechnology, Inc. is a clinical-stage drug discovery company developing innovative drugs for the treatment of human cancers. Their mission is to discover drugs that inhibit the signaling pathways critical to the growth and survival of cancer cells. Lixte combines cutting-edge molecular biology and computational chemistry approaches to screen for promising anti-cancer compounds, with a focus on targeting enzymes involved in tumor development and progression. Through rigorous research and development practices, Lixte aims to improve the lives of cancer patients by providing effective and personalized treatment options.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

27 Patents

#24 in Pasadena, CA

#2,846 in California

#11,991 in US

#23,273 in the World

Pasadena, CA, United States of America

Lixte Biotechnology, Inc.

Forward Citations = 268

15 inventors:

John S Kovach (26 out of 30 patents)

Francis Johnson (10 out of 30 patents)

Robert A Volkmann (5 out of 73 patents)

4. Anthony Marfat (5 out of 62 patents)

5. Mickey L Wells (3 out of 3 patents)

Please report any incorrect information to support@idiyas.com

Loading…